Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Document › Details

Polares Medical S.A.. (7/17/18). "Press Release: Polares Medical Closes a $25m Financing to Enter Clinical Validation". Lausanne & Palo Alto, CA.

Organisations Organisation Polares Medical S.A.
  Group Polares Medical (Group)
  Organisation 2 Decheng Capital
Products Product valve (medical)
  Product 2 venture capital
Index terms Index term Polares Medical–SEVERAL: investment, 201807 financing round $25m led by Decheng Capital
  Index term 2 Polares Medical–Endeavour Vision: investment, 201807 financing round totalling $25m incl co-investor Endeavour Vision
Persons Person Pliam, Nick (Decheng Capital 201807 Prinipal)
  Person 2 Essinger, Jacques R. (Symetis 201703 CEO)

Polares Medical SA, a preclinical stage medical technology company focused on the development of a unique trans-catheter mitral valve hemi-replacement system to treat patients suffering from mitral regurgitation (MR), announced today the closing of a $25 million financing led by Decheng Capital (Menlo Park and Shanghai) together with Endeavour Vision (Geneva), IDO Investments (Muscat), Earlybird Venture Capital (Berlin) and Wellington Partners (Munich).

Polares Medical’s solution to MR is based on the original concept of hemi-replacement of the mitral valve, i.e. the replacement of the posterior leaflet with a prosthetic leaflet designed to enhance coaptation with the native anterior leaflet.

“Hemi-replacement represents a new treatment paradigm for mitral regurgitation, between repair and total replacement. We believe this approach has the potential to provide an effective addition to the armamentarium for the percutaneous treatment of MR,” said Decheng Principal Nick Pliam, MD, Ph.D.

Polares Medical was created as a spin-off of Symetis SA to develop the mitral technology that Symetis obtained through its acquisition of Middle Peak Medical GmbH, prior to Boston Scientific Corporation’s acquisition of Symetis in 2017.

“This investment allows Polares to bring our technology to clinical evaluation, and to unleash its potential as a game-changer in MR treatment.” said Jacques Essinger, Ph.D, Chairman and CEO.


Polares Medical SA
+41 21 310 11 20

+1 (650) 233-0688

Record changed: 2018-07-18


Picture [LSA] – The Business Web Portal 650x89px

More documents for Polares Medical (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

» top